Table 2.
Summary of clinicopathological data of the enrolled cases.
| Clinicopathological Parameters | No. (%) | |||
|---|---|---|---|---|
| Age (yrs) | Ranged 36–82 | Mean 63.0 ± 9.4 | ||
| Sex | Male 70, Female 45 | M:F = 1.52:1 | ||
| ASA status score | ||||
| Score 1 | 10 | (8.69%) | ||
| Score 2 | 103 | (89.56%) | ||
| Score 3 | 2 | (1.73%) | ||
| Location (tumor epicenter) | ||||
| AOV | 32 | (27.82%) | ||
| Pancreatic head | 38 | (33.04%) | ||
| Distal CBD | 45 | (39.13%) | ||
| T stage | T7 | T8 | ||
| Tis | 1 | (0.86%) | 1 | (0.86%) |
| T1 | 20 | (17.39%) | 25 | (25.73%) |
| T2 | 28 | (24.34%) | 53 | (46.08%) |
| T3 | 58 | (50.43%) | 29 | (25.21%) |
| T4 | 8 | (6.95%) | 7 | (6.08%) |
| Gross type Fungating | 20 | (17.39%) | ||
| Infiltrative | 83 | (72.17%) | ||
| Ulcerofungating | 3 | (2.6%) | ||
| Sessile | 4 | (3.47%) | ||
| Solid | 2 | (1.73%) | ||
| Tumor size | Ranged 0.6–8.0 cm | Mean 3.2 ± 1.6cm | ||
| <4.5 cm | 88 | (76.53%) | ||
| ≥4.5 cm | 27 | (23.47%) | ||
| N stage N0 | 66 | (57.40%) | ||
| N1 | 49 | (42.60%) | ||
| N2 | 0 | (0%) | ||
| M stage M0 | 107 | (93.04%) | ||
| M1 | 8 | (6.96%) | ||
| Absent | Present | |||
| Lymphatic invasion | 64 | (55.65%) | 51 | (44.35%) |
| Vascular invasion | 101 | (87.82%) | 14 | (12.18%) |
| Perineural invasion | 48 | (41.73%) | 67 | (58.26%) |
| Positive radial resected margin | 107 | (93.04%) | 8 | (6.96%) |
| Tumor ulceration | 106 | (92.17%) | 9 | (7.83%) |
| Histologic grade | ||||
| Well-differentiated | 30 | (26.08%) | ||
| Moderately-differentiated | 81 | (70.43%) | ||
| Poorly-differentiated | 4 | (3.47%) | ||
| Histologic subtype | ||||
| Pancreaticobiliary subtype | 30 | (26.08%) | ||
| Prone to pancreaticobiliary subtype | 54 | (46.95%) | ||
| Prone to intestinal subtype | 16 | (13.91%) | ||
| Intestinal subtype | 14 | (12.17%) | ||
| Degree of fibrosis | ||||
| Absent | 4 | (3.47%) | ||
| Mild | 20 | (17.39%) | ||
| Moderate | 64 | (55.65%) | ||
| Severe | 27 | (23.47%) | ||
| Degree of inflammation | ||||
| Mild | 39 | (33.91%) | ||
| Moderate | 63 | (54.78%) | ||
| Severe | 13 | (11.30%) | ||
| Tumor recurrence | Absent | Present | ||
| 56 | (48.69%) | 52 | (45.21%) | |
| Death | 37 | (32.17%) | 78 | (67.82.%) |
| Follow-up duration (days) | Ranged 3–5234 | 969.7 ± 1135 | ||
| Disease free survival (days) | Ranged 3–4173 | 731.2 ± 954.5 | ||